Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Paxila Launches Comprehensive Turkey Tour Packages: Explore Ephesus, Cappadocia, and More
-
Global Cloud Mining: Opening a New Chapter of Cryptocurrency
-
Digi-Peak: Empowering Users to Create a Safer Digital Cryptocurrency Environment
-
Belffin - A New Standard In Cozy, Customisable Seating
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages FMC Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - FMC
-
Penry Air CEO Casey Penry Highlights the Future of Energy-Efficient Compressed Air Technology.
-
KOIL Energy Announces Delay in Filing of Annual Report on Form 10-K and anticipates reporting profitable growth in revenues
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atkore Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATKR
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Flywire Corporation Investors to Inquire About Securities Class Action Investigation - FLYW
-
Ambia Solar Headquarters Move to Lindon, Utah
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - APP
-
TOP RANKED ROSEN LAW FIRM Encourages Alarum Technologies Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALAR
-
Hisense Broadband Multimedia Technologies Co., Ltd. (HBMT) forms Ligent Inc. by Consolidating North American and Thailand Operations
-
GSK FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
DNB Financial Group Launches Zero-Commission Stock Trading for UK Investors
-
GlobalInterTec Targets 1 Million Users as Expansion Accelerates
-
NMRA FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by
-
GivBux Details $212 Million Strategic Investment; Commits $212 Million to an Asset-Based Investment Vehicle
-
NEM DEADLINE TUESDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Newmont Corporation Investors to Secure Counsel Before Important April 1 Deadline in Securities Class Action - NEM
-
HII Celebrates 2024 Graduates of The Newport News Shipbuilding Apprentice School
-
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Ris
-
Think you can do better than your team's GM? Ultra GM gives you that chance.
-
Family of Yuyu Dong (outside of China) Available After Appeals Hearing Monday
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
-
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Purchasers of Nike NFTs Issued by RTFKT, Inc. to Inquire About Class Action Investigation
-
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
-
Investing in the Future of Digital Privacy: Digi-Peak Token (DPT) Officially Launches ICO
-
Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
-
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual
-
With Renovation Approaching, Final Dubai Fountain Show Date Unveiled
-
Vivendi Signs an Agreement With Poste Italiane for the Sale of TIM Shares
-
World’s First Vibe Coding Competition Announced at RALLY Conference
-
GROKSTER ($GRK): THE FIRST AI-CLAIMED MASCOT TOKEN LAUNCHES ON BASE CHAIN
-
Breaking Down Hyper Test: Benefits and Use Cases
-
Sycamine Capital Management Forecasts Asia Fintech Boom
-
International Top-Up and Natcash Remittance: Transforming Connectivity and Financial Empowerment in Haiti with NATCOM
-
Pelangio Exploration Announces Closing of Private Placement for Gross Proceeds of $1,000,000
-
Explore the 2025 Ford Bronco Trim Level Research: Find Your Perfect Off-Road Adventure Companion at Akins Ford near Atlanta, GA
-
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Sess
-
UtahRealEstate.com Partners with Inside Real Estate to Give Members an Advertising Platform to Promote Listings on Facebook and Instagram
-
How Medical Malpractice Cases Work in Florida: What Victims Need to Know
-
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring
-
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requi
-
TIXT DEADLINE MONDAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TELUS International (Cda) Inc. Investors to Secure Counsel Before Important March 31 Deadline in Securities Class Action - TIXT
-
Saephan Companies Join the Unicorn Market: Johny Saephan Becomes First Mien-Thai American AI Billionaire with $1B Pre-Valuation Tied to Aisles Investment
-
Franchise FastLane Partners with MaxStrength Fitness to Propel Growth
-
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
-
BexBack Launches 100x Leverage, Double Deposit Bonus, and $50 Welcome Bonus — No KYC Required
-
Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD)
-
Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25
